ProStrakan Group plc , the international specialty pharmaceutical company, today announces that it has received approval from the US Food and Drug Administration (FDA) for Sancuso®, ProStrakan’s novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).

ProStrakan expects to launch Sancuso in the US before the end of 2008 – its first product launch in the US. Sancuso, the world’s first licensed transdermal 5HT3 receptor antagonist product, will be launched into a market worth $1.3 billion in the US alone As a patch.  Sancuso offers cancer sufferers who are at risk of severe nausea & vomiting a new, patient-friendly treatment choice that is both non-invasive and non-oral. Sancuso was developed in-house by ProStrakan – from inception to launch in five years. Sancuso will be marketed by an exclusive US sales force, currently being established by ProStrakan in collaboration with NovaQuest (the partnering group of Quintiles)

ProStrakan has already established its US head office in Bedminster, New Jersey, and has recruited an experienced management team. Its US National Sales Manager is in place, together with seven Medical Science Liaison team-members, who have now been trained and will liaise with Oncologists and Oncology Nurses across the US.  The Company will continue to work in collaboration with its US strategic partner, NovaQuest (the managed partnership group of Quintiles Transnational Corp.), to deploy its 67-strong national sales force.